Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Swiss health ministry data shows vaccinated people seldom hit by COVID-19

06/24/2021 | 12:36pm EDT

ZURICH, June 24 (Reuters) - Switzerland's move to allow large public events with 10,000-plus people from Saturday comes as government data appears to show vaccines are helping control new infections that are mostly hitting people who remain unprotected.

Only 209 of 180,000 new infections recorded in Switzerland between Jan. 27 and June 21 were in people fully vaccinated with shots from Moderna or Pfizer and Germany's BioNTech, according to Swiss Federal Health Ministry data provided to Reuters on Thursday.

The ministry said the vast majority of these so-called breakthrough cases -- infections of fully vaccinated people -- that were studied using genetic sequencing involved the Alpha variant, first recorded in Britain and which began spreading in Switzerland around the new year.

Just a single breakthrough infection has been reported for the more infectious Delta variant, first documented in India and now causing concern globally as it fast becomes the dominant variant.

"There is currently no evidence that the Delta variant leads to more vaccine breakthroughs than Alpha," a Health Ministry spokesman said.

However there is emerging, and sometimes conflicting, data regarding the Delta variant's threat.

One study, from Scotland, indicated the Delta variant may double hospitalization risk.

In another, Pfizer and AstraZeneca vaccines were judged effective against the variant, while yet another https://www.researchsquare.com/article/rs-637724/v1 from a U.K. and Indian group concluded Delta's rapid growth was "most likely explained by a combination of increased transmissibility and immune evasion" including vaccine escape.

England, which has delayed fully reopening as cases rise despite high vaccination rates, has trimmed the recommended gap between first and second COVID-19 shots to eight weeks from 12 for some groups of the population, because of the fast-spreading Delta variant and data showing protection is much higher after the second dose.

In Switzerland, 2.6 million of its 8.6-million-person population have received two doses of mRNA vaccines from Moderna and Pfizer, the only two available in the country.

Another 1.5 million people have received a single shot and are awaiting a booster. (Reporting by John Miller in Zurich, Josephine Mason in London and Christine Soares in New York, Editing by William Maclean)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.16% 8266 Delayed Quote.12.68%
MODERNA, INC. 5.90% 348.2275 Delayed Quote.214.44%
PFIZER, INC. 3.63% 43.65 Delayed Quote.14.37%
All news about ASTRAZENECA PLC
10:26aASTRAZENECA : UK To Start Delivering COVID-19 Jabs To Other Countries
09:42aREGENERON PHARMACEUTICALS : And astrazeneca to research develop and commercializ..
07:21aASTRAZENECA : No increased blood clot risk after second dose of AstraZeneca
06:06aJOHNSON & JOHNSON : 'Do Not Take J & J Vaccine If You Have Taken Astrazeneca' - ..
04:29aASTRAZENECA : Jab Shows Similar Rates Of Clotting Disorder With Unvaccinated Pop..
03:25aHUTCHMED CHINA : AstraZeneca Begin Mid-Stage Trial For Gastric Cancer Drug
03:05aAstraZeneca Says Covid-19 Vaccine Showed No Increased Incidence of Thrombosis..
02:28aASTRAZENECA : Rare blood clot cases not higher after AstraZeneca second dose- st..
02:13aASTRAZENECA : Vaxzevria showed no increased incidence of thrombosis with thrombo..
02:13aASTRAZENECA : Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable..
More news
Financials (USD)
Sales 2021 35 226 M - -
Net income 2021 5 466 M - -
Net Debt 2021 18 482 M - -
P/E ratio 2021 31,0x
Yield 2021 2,46%
Capitalization 177 B 177 B -
EV / Sales 2021 5,56x
EV / Sales 2022 4,48x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 114,56 $
Average target price 132,25 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.68%177 459
JOHNSON & JOHNSON9.71%454 682
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.14.37%235 663
NOVARTIS AG-0.44%221 987